Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC + Toripalimab in Bladder-preserving Treatment
NCT07201675Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin in bladder carcinoma, sponsored by Qilu Hospital of Shandong University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
bladder carcinoma
Beyond the preview
Go deeper on NCT07201675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07201675.